Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data
Executive Summary
Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.
You may also be interested in...
Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
A Strong Start For Amvuttra, But Alnylam Bides Time On Heart Results And US Price Control Plans
Alnylam has scrapped plans for an interim analysis of its all-important HELIOS-B study of its new ATTR therapy, hoping that a 2024 readout will be more compelling, while the US Inflation Reduction Act has put the brakes on development in another indication.
Finance Watch: Third Harmonic Launches The Largest IPO In Months
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.